0.35 (0.14%)
  • Advice
  • Hold
As on 08 June, 2023 | 03:37 BSE: 532523 NSE: BIOCON

Biocon Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Biocon

Start SIP

Biocon Share Price

  • Over 1 Month 0.35%
  • Over 3 Month 7.64%
  • Over 6 Month -11.62%
  • Over 1 Year -23.06%

Biocon Key Statistics

P/E Ratio 63.2
PEG Ratio -2.2
Market Cap Cr 29,259
Price to Book Ratio 1.3
EPS 0.9
Dividend 0.2
Relative Strength Index 57.01
Money Flow Index 60.89
MACD Signal 2.82
Average True Range 5.87

Biocon Investment Rating

  • Master Rating:
  • Biocon (Nse) has an operating revenue of Rs. 11,174.20 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 10% is healthy, ROE of 2% is fair but needs improvement. The company has a debt to equity of 86%, which is bit higher. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 138 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Biocon Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 507555490442518
Operating Expenses Qtr Cr 551518462439491
Operating Profit Qtr Cr -443728327
Depreciation Qtr Cr 2929302928
Interest Qtr Cr 4821000
Tax Qtr Cr -1511119821
Net Profit Qtr Cr 1,811359881538

Biocon Technicals


Current Price
0.35 (0.14%)
  • Bullish Moving Average
  • ___
  • 13
  • Bearish Moving Average
  • ___
  • 3
  • 20 Day
  • ₹241.63
  • 50 Day
  • ₹237.16
  • 100 Day
  • ₹240.31
  • 200 Day
  • ₹258.3
  • 20 Day
  • ₹243.27
  • 50 Day
  • ₹232.01
  • 100 Day
  • ₹232.4
  • 200 Day
  • ₹256.87

Biocon Resistance and Support

First Resistance ₹244.95
Second Resistance ₹246.55
Third Resistance ₹249.1
RSI 57.01
MFI 60.89
MACD Single Line 2.82
MACD 2.11
First Resistance ₹240.8
Second Resistance ₹238.25
Third Resistance ₹236.65

Biocon Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 2,375,943 104,375,176 43.93
Week 3,614,062 135,129,793 37.39
1 Month 3,607,699 134,639,333 37.32
6 Month 4,466,074 192,353,827 43.07

Biocon Result Highlights

Biocon Synopsis


Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1992.90 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2023. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
Market Cap 29,259
Sales 1,993
Shares in Float 46.82
No of funds 286
Yield 0.62
Book Value 2.68
U/D Vol ratio 1.3
LTDebt / Equity 12
Alpha -0.13
Beta 0.7


Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 60.64%60.64%60.64%60.64%
Mutual Funds 7.19%3.95%3.21%3.05%
Insurance Companies 4.68%4.68%4.55%4.25%
Foreign Portfolio Investors 10.2%14.42%15.79%16.31%
Financial Institutions/ Banks
Individual Investors 13.2%12.47%12.07%10.72%
Others 4.09%3.84%3.74%5.03%

Biocon Management

Name Designation
Mr. Siddharth Mittal Managing Director & CEO
Ms. Kiran Mazumdar Shaw Executive Chairperson
Mr. John Shaw Vice Chairman & Non Exe.Dire
Prof. Ravi Mazumdar Non Executive Director
Mr. Mary Harney Independent Director
Mr. Daniel M Bradbury Independent Director
Dr. Vijay Kuchroo Independent Director
Mr. M Damodaran Independent Director
Mr. Bobby Kanubhai Parikh Independent Director

Biocon Forecast

Price Estimates


Other Analyst Rating

Biocon Corporate Action

Date Purpose Remarks
2023-05-23 Audited Results & Final Dividend
2023-04-26 Others To consider, Fund Raising. per share(20%)Final Dividend
2023-02-14 Quarterly Results
2022-11-14 Quarterly Results
2022-07-27 Quarterly Results
Date Purpose Remarks
2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

Biocon MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 54413
ICICI Prudential Bluechip Fund Growth 35877
Mirae Asset Large Cap Fund Regular Growth 33926
ICICI Prudential Value Discovery Fund Growth 28471
Mirae Asset Emerging Bluechip Fund Growth 24541

About Company

Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bangalore, India. The company has more than 13,500  employees. It focuses on all phases of the product cycle from researching to development and then introducing them to the market.  They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine), etc. 


History of Biocon limited 

Biocon Limited was incorporated in 1978. It is  India's largest pharmaceutical company. During incorporation, it was a joint venture between Biocon Biochemicals Limited Ireland and an Indian entrepreneur Kiran Mazumdar-Shaw. Biocon started its journey by exporting enzymes to the USA and Europe.

In the year 1989 Unilever Acquired Biocon’s Irish Parent and merged with Quest International. 

In 2004, Biocon limited entered into a 9-year contract with the US to supply recombinant human insulin and in July 2004, the company said that its Cuban partner CIMAB ( center for molecular immunology ) with Biocon licensed out three experimental cancer drugs to a Biotechnology Company, CancerVax. 

In 2005, Biocon signed a memorandum of understanding with the Karolinska Institute. The CMD of Biocon Limited, Kiran Mazumdar-Shaw was honoured with the corporate leadership award. 

In 2006, The company tied up with ICICI prudential life insurance and finished phase-4 trials of insulin. 

In 2009, Biocon joined hands with Mylan pharmaceuticals.

In 2010, The company invested in Malaysia partnering with Biotechcorp. 

Biocon FAQs

What is Share Price of Biocon ?

Biocon share price is ₹243 As on 08 June, 2023 | 03:23

What is the Market Cap of Biocon ?

The Market Cap of Biocon is ₹29258.6 Cr As on 08 June, 2023 | 03:23

What is the P/E ratio of Biocon ?

The P/E ratio of Biocon is 63.2 As on 08 June, 2023 | 03:23

What is the PB ratio of Biocon ?

The PB ratio of Biocon is 1.3 As on 08 June, 2023 | 03:23

Is it a good time to invest in Biocon Limited?

Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

How many times has Biocon Limited given dividends since 2004?

Biocon Ltd. has declared 17 dividends since July 1, 2004.

What is the stock price CAGR of Biocon Limited?

The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

What is the debt-to-equity ratio of Biocon Limited?

The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

What is the ROE of the Biocon Limited?

The ROE of Biocon Limited is 9% which is fair but needs improvement.

Who is the Managing Director of Biocon Limited?

Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

Is Biocon a good stock to buy?

According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

What is the revenue of Biocon?

The revenue of Biocon for FY22 is Rs. 8184 Cr.

How to buy shares of Biocon Ltd?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.


Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number